JP2003509029A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003509029A5 JP2003509029A5 JP2001522406A JP2001522406A JP2003509029A5 JP 2003509029 A5 JP2003509029 A5 JP 2003509029A5 JP 2001522406 A JP2001522406 A JP 2001522406A JP 2001522406 A JP2001522406 A JP 2001522406A JP 2003509029 A5 JP2003509029 A5 JP 2003509029A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- expression
- luciferase
- gene
- light
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000014509 gene expression Effects 0.000 description 191
- 108090000623 proteins and genes Proteins 0.000 description 115
- 102000040430 polynucleotide Human genes 0.000 description 103
- 108091033319 polynucleotide Proteins 0.000 description 103
- 239000002157 polynucleotide Substances 0.000 description 103
- 108060001084 Luciferase Proteins 0.000 description 87
- 210000004027 cell Anatomy 0.000 description 86
- 239000005089 Luciferase Substances 0.000 description 76
- 238000000034 method Methods 0.000 description 71
- 241000894006 Bacteria Species 0.000 description 58
- 108020004414 DNA Proteins 0.000 description 48
- 101150000296 luxA gene Proteins 0.000 description 46
- 238000005415 bioluminescence Methods 0.000 description 42
- 241000192125 Firmicutes Species 0.000 description 40
- 101150065800 luxB gene Proteins 0.000 description 40
- 230000029918 bioluminescence Effects 0.000 description 39
- 239000013612 plasmid Substances 0.000 description 37
- 150000001299 aldehydes Chemical class 0.000 description 36
- 108091026890 Coding region Proteins 0.000 description 35
- 241001465754 Metazoa Species 0.000 description 32
- 241000588724 Escherichia coli Species 0.000 description 31
- 108090000765 processed proteins & peptides Proteins 0.000 description 31
- 239000000758 substrate Substances 0.000 description 30
- 230000001580 bacterial effect Effects 0.000 description 29
- 230000002708 enhancing effect Effects 0.000 description 29
- 239000012634 fragment Substances 0.000 description 27
- 150000007523 nucleic acids Chemical class 0.000 description 27
- 239000013598 vector Substances 0.000 description 27
- 238000003780 insertion Methods 0.000 description 26
- 230000037431 insertion Effects 0.000 description 26
- 102000004196 processed proteins & peptides Human genes 0.000 description 26
- 229920001184 polypeptide Polymers 0.000 description 25
- 239000012491 analyte Substances 0.000 description 24
- 239000013605 shuttle vector Substances 0.000 description 24
- 239000002773 nucleotide Substances 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 21
- 102000039446 nucleic acids Human genes 0.000 description 20
- 108020004707 nucleic acids Proteins 0.000 description 20
- 125000003729 nucleotide group Chemical group 0.000 description 20
- 108091028043 Nucleic acid sequence Proteins 0.000 description 17
- 150000001413 amino acids Chemical class 0.000 description 17
- 238000013518 transcription Methods 0.000 description 17
- 230000035897 transcription Effects 0.000 description 17
- 238000012216 screening Methods 0.000 description 16
- 238000010367 cloning Methods 0.000 description 15
- 101150005370 luxC gene Proteins 0.000 description 15
- 230000010076 replication Effects 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 14
- 238000009396 hybridization Methods 0.000 description 14
- 238000003384 imaging method Methods 0.000 description 14
- 101150112190 luxD gene Proteins 0.000 description 14
- 101150059295 luxE gene Proteins 0.000 description 14
- 238000012544 monitoring process Methods 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- 238000011144 upstream manufacturing Methods 0.000 description 12
- 101100344153 Aliivibrio fischeri luxY gene Proteins 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 241001148064 Photorhabdus luminescens Species 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000010276 construction Methods 0.000 description 10
- 230000029087 digestion Effects 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- 230000027455 binding Effects 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 9
- 238000013519 translation Methods 0.000 description 9
- 230000014616 translation Effects 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 210000003527 eukaryotic cell Anatomy 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 239000002023 wood Substances 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 108091081024 Start codon Proteins 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000186779 Listeria monocytogenes Species 0.000 description 6
- 241000823609 Staphylococcus aureus subsp. aureus RN4220 Species 0.000 description 6
- 241000194017 Streptococcus Species 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- KSMVZQYAVGTKIV-UHFFFAOYSA-N decanal Chemical compound CCCCCCCCCC=O KSMVZQYAVGTKIV-UHFFFAOYSA-N 0.000 description 6
- 238000004020 luminiscence type Methods 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- 241000271566 Aves Species 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 229930027917 kanamycin Natural products 0.000 description 5
- 229960000318 kanamycin Drugs 0.000 description 5
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 5
- 229930182823 kanamycin A Natural products 0.000 description 5
- 101150066555 lacZ gene Proteins 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 210000001236 prokaryotic cell Anatomy 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 210000000689 upper leg Anatomy 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 244000063299 Bacillus subtilis Species 0.000 description 4
- 235000014469 Bacillus subtilis Nutrition 0.000 description 4
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 4
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 4
- 241000021375 Xenogenes Species 0.000 description 4
- 244000052616 bacterial pathogen Species 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 229960005091 chloramphenicol Drugs 0.000 description 4
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 4
- 235000019219 chocolate Nutrition 0.000 description 4
- 230000001332 colony forming effect Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 238000009630 liquid culture Methods 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 239000002853 nucleic acid probe Substances 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 230000007918 pathogenicity Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- YTNIXZGTHTVJBW-SCRDCRAPSA-N FMNH2 Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2NC2=C1NC(=O)NC2=O YTNIXZGTHTVJBW-SCRDCRAPSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241001665537 Idiocerus aureus Species 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 3
- 102000003960 Ligases Human genes 0.000 description 3
- 241000186781 Listeria Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 241001148062 Photorhabdus Species 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000006862 enzymatic digestion Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000004907 flux Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000002463 transducing effect Effects 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- -1 Amino Chemical group 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- 241000193738 Bacillus anthracis Species 0.000 description 2
- 241000254173 Coleoptera Species 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
- 229930195713 D-glutamate Natural products 0.000 description 2
- 108010071146 DNA Polymerase III Proteins 0.000 description 2
- 102000007528 DNA Polymerase III Human genes 0.000 description 2
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
- 108090000331 Firefly luciferases Proteins 0.000 description 2
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
- 108010047357 Luminescent Proteins Proteins 0.000 description 2
- 102000006830 Luminescent Proteins Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241000186359 Mycobacterium Species 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 241000607568 Photobacterium Species 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 206010044248 Toxic shock syndrome Diseases 0.000 description 2
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 241000607598 Vibrio Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 230000005670 electromagnetic radiation Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 108010075712 fatty acid reductase Proteins 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 2
- HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 231100000582 ATP assay Toxicity 0.000 description 1
- 102000021527 ATP binding proteins Human genes 0.000 description 1
- 108091011108 ATP binding proteins Proteins 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000607620 Aliivibrio fischeri Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108700025440 Bacillus subtilis DnaI Proteins 0.000 description 1
- 108700008484 Bacillus subtilis LytE Proteins 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 108090000363 Bacterial Luciferases Proteins 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 101710149968 Cell division protein DivIB Proteins 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- YCAGGFXSFQFVQL-UHFFFAOYSA-N Endothion Chemical compound COC1=COC(CSP(=O)(OC)OC)=CC1=O YCAGGFXSFQFVQL-UHFFFAOYSA-N 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000391102 Epipyxis aureus Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000156978 Erebia Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 208000034454 F12-related hereditary angioedema with normal C1Inh Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 241000224466 Giardia Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000694017 Homo sapiens Sodium channel protein type 5 subunit alpha Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241000203407 Methanocaldococcus jannaschii Species 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 101710097941 N-acetylmuramoyl-L-alanine amidase CwlA Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 241000254064 Photinus pyralis Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241001427617 Pyrophorus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000098700 Sarcocheilichthys parvus Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000863430 Shewanella Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 101900245696 Staphylococcus aureus Thioredoxin Proteins 0.000 description 1
- 241000694196 Streptococcus pneumoniae R6 Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- NQBRVZNDBBMBLJ-MQTLHLSBSA-K UDP-N-acetyl-alpha-D-muramate(3-) Chemical group CC(=O)N[C@@H]1[C@@H](O[C@H](C)C([O-])=O)[C@H](O)[C@@H](CO)O[C@@H]1OP([O-])(=O)OP([O-])(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 NQBRVZNDBBMBLJ-MQTLHLSBSA-K 0.000 description 1
- 108010074827 UDP-N-acetylglucosamine-N-acetylmuramyl-(pentapeptide)pyrophosphoryl-undecaprenol N-acetylglucosamine transferase Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000607757 Xenorhabdus Species 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000000787 affinity precipitation Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002257 antimetastatic agent Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 235000010633 broth Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 239000007330 chocolate agar Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 150000002192 fatty aldehydes Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 208000016861 hereditary angioedema type 3 Diseases 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 229940015418 ketaset Drugs 0.000 description 1
- 239000003041 laboratory chemical Substances 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 101150114389 luxY gene Proteins 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 101150037968 murG gene Proteins 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 101150059999 pro gene Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 101150116440 pyrF gene Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15290499P | 1999-09-08 | 1999-09-08 | |
| US60/152,904 | 1999-09-08 | ||
| PCT/US2000/024699 WO2001018195A2 (en) | 1999-09-08 | 2000-09-07 | Luciferase expression cassettes and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010256354A Division JP5295206B2 (ja) | 1999-09-08 | 2010-11-16 | ルシフェラーゼ発現カセットおよび使用法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003509029A JP2003509029A (ja) | 2003-03-11 |
| JP2003509029A5 true JP2003509029A5 (https=) | 2011-01-13 |
| JP4669180B2 JP4669180B2 (ja) | 2011-04-13 |
Family
ID=22544956
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001522406A Expired - Lifetime JP4669180B2 (ja) | 1999-09-08 | 2000-09-07 | ルシフェラーゼ発現カセットおよび使用法 |
| JP2010256354A Expired - Fee Related JP5295206B2 (ja) | 1999-09-08 | 2010-11-16 | ルシフェラーゼ発現カセットおよび使用法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010256354A Expired - Fee Related JP5295206B2 (ja) | 1999-09-08 | 2010-11-16 | ルシフェラーゼ発現カセットおよび使用法 |
Country Status (8)
| Country | Link |
|---|---|
| EP (2) | EP1728866B1 (https=) |
| JP (2) | JP4669180B2 (https=) |
| AT (2) | ATE448309T1 (https=) |
| AU (1) | AU779263B2 (https=) |
| CA (1) | CA2384496A1 (https=) |
| DE (2) | DE60043321D1 (https=) |
| ES (1) | ES2267561T3 (https=) |
| WO (1) | WO2001018195A2 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7255851B2 (en) | 1994-07-01 | 2007-08-14 | The Board Of Trustees Of The Leland Stanford Junior University | Non-invasive localization of a light-emitting conjugate in a mammal |
| US6649143B1 (en) | 1994-07-01 | 2003-11-18 | The Board Of Trustees Of The Leland Stanford Junior University | Non-invasive localization of a light-emitting conjugate in a mammal |
| AU774183B2 (en) | 1998-12-17 | 2004-06-17 | Xenogen Corporation | Non-invasive evaluation of physiological response in a mammal |
| US6610503B1 (en) | 1999-03-17 | 2003-08-26 | Xenogen Corporation | Animal models for predicting sepsis mortality |
| US6737245B1 (en) | 1999-09-08 | 2004-05-18 | Xenogen Corporation | Luciferase expression cassettes and methods of use |
| US6867348B1 (en) | 1999-12-16 | 2005-03-15 | Xenogen Corporation | Methods and compositions for screening for angiogenesis modulating compounds |
| IT1311335B1 (it) | 1999-12-21 | 2002-03-12 | Otc Optical Technologies Ct S | Procedimento e dispositivo per realizzare reticoli in fibra ottica. |
| US7056728B2 (en) | 2000-07-06 | 2006-06-06 | Xenogen Corporation | Compositions and methods for use thereof in modifying the genomes of microorganisms |
| US6858773B2 (en) | 2001-04-20 | 2005-02-22 | Xenogen Corporation | Transgenic mice comprising transcription control elements associated with mouse eosinophil peroxidase expression |
| CA2452876A1 (en) * | 2001-07-09 | 2003-01-23 | Anticancer, Inc. | Imaging infection using fluorescent protein as a marker |
| EP1281772A1 (en) * | 2001-07-31 | 2003-02-05 | Aladar A. Szalay | Light-emitting microorganisms and cells for tumour diagnosis/therapy |
| EP1281767A3 (en) * | 2001-07-31 | 2003-05-28 | Aladar A. Szalay | Light emitting microorganisms and cells for diagnosis and therapy of tumors |
| EP1644492B1 (en) | 2003-06-18 | 2009-01-07 | Genelux Corporation | Modified recombinant vaccinia viruses, uses thereof |
| EP2426142A3 (en) | 2006-10-16 | 2012-06-13 | Genelux Corporation | Modified vaccinia virus strains for use in a diagnostic and therapeutic method |
| US7910087B2 (en) | 2007-03-02 | 2011-03-22 | University Of Massachusetts | Luciferins |
| WO2015031859A1 (en) * | 2013-08-29 | 2015-03-05 | The Regents Of The University Of California | Bacteria engineered for ester production |
| WO2020243660A1 (en) | 2019-05-30 | 2020-12-03 | 490 BioTech, Inc. | Lux expression in cells and methods of use |
| CN110295181B (zh) * | 2019-06-18 | 2022-10-11 | 山东大学 | 一种利用生物发光报告系统鉴定抗生素种类的方法 |
| DE102020129009A1 (de) | 2020-11-04 | 2022-05-05 | Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen, Körperschaft des öffentlichen Rechts | Nachweis von umwelteinflüssen mittels biolumineszenz |
| CN113403243B (zh) * | 2021-06-16 | 2022-07-19 | 中国人民解放军军事科学院军事医学研究院 | 基于lux报告系统的猪链球菌发光菌及其构建方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU219827B (hu) * | 1992-10-02 | 2001-08-28 | Lonza Ag. | Biotechnológiai eljárás biotin előállítására |
| FI96697C (fi) * | 1993-08-18 | 2001-05-16 | Valio Oy | Uudet Streptococcus thermophilus -kannat ja niiden käyttö antibioottie n määrittämiseen |
| JP2001516573A (ja) * | 1997-09-18 | 2001-10-02 | スミスクライン・ビーチャム・コーポレイション | 抗微生物化合物のスクリーニング方法 |
-
2000
- 2000-09-07 DE DE60043321T patent/DE60043321D1/de not_active Expired - Lifetime
- 2000-09-07 EP EP06009933A patent/EP1728866B1/en not_active Expired - Lifetime
- 2000-09-07 CA CA002384496A patent/CA2384496A1/en not_active Abandoned
- 2000-09-07 AU AU71266/00A patent/AU779263B2/en not_active Ceased
- 2000-09-07 AT AT06009933T patent/ATE448309T1/de not_active IP Right Cessation
- 2000-09-07 EP EP00960044A patent/EP1212429B1/en not_active Expired - Lifetime
- 2000-09-07 ES ES00960044T patent/ES2267561T3/es not_active Expired - Lifetime
- 2000-09-07 WO PCT/US2000/024699 patent/WO2001018195A2/en not_active Ceased
- 2000-09-07 JP JP2001522406A patent/JP4669180B2/ja not_active Expired - Lifetime
- 2000-09-07 AT AT00960044T patent/ATE331790T1/de not_active IP Right Cessation
- 2000-09-07 DE DE60029107T patent/DE60029107T2/de not_active Expired - Lifetime
-
2010
- 2010-11-16 JP JP2010256354A patent/JP5295206B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5295206B2 (ja) | ルシフェラーゼ発現カセットおよび使用法 | |
| JP2003509029A5 (https=) | ||
| KR102594240B1 (ko) | 신규한 루시퍼라제 및 이를 이용하는 방법 | |
| Patterson et al. | Codon optimization of bacterial luciferase (lux) for expression in mammalian cells | |
| RU2730038C2 (ru) | Ферменты биосинтеза люциферина и их применение | |
| US6737245B1 (en) | Luciferase expression cassettes and methods of use | |
| US7056728B2 (en) | Compositions and methods for use thereof in modifying the genomes of microorganisms | |
| AU2002258480B2 (en) | Methods of screening for introduction of DNA into a target cell | |
| JP2025522599A (ja) | ルシフェラーゼ変異体及びその使用 | |
| JP2003093047A (ja) | 環境因子の測定に用いる微生物 | |
| RU2809367C2 (ru) | Гиспидин-синтазы и их применение | |
| RU2812474C2 (ru) | Кофеилпируват-гидролазы и их применение | |
| KR101387288B1 (ko) | 구토독 산생 세레우스균의 검출 방법 및 상기 방법을 위한 프라이머 세트 | |
| RU2822532C2 (ru) | Поликетидсинтазы III типа и их применение | |
| WO2002008431A1 (en) | Compositions and methods for use thereof in modifying the genomes of microorganisms | |
| WO2023109981A9 (zh) | 新型桡足类荧光素酶突变体及其应用 | |
| Patterson | Optimization of bacterial luciferase for expression in mammalian cells | |
| BR122025022833A2 (pt) | Novas luciferases e métodos de uso destas | |
| KR20100032956A (ko) | 융합 파트너로 이용해 리포터로 사용이 가능한 에스테라아제(ｅｓｔｌ120ｐ)와 이를 인디케이터로 이용한 클로닝 벡터의 제조방법 |